(Open access funding provided by Semmelweis University)
Multiple myeloma (MM) is an incurable plasma cell malignancy, which is predominantly
a disease of older adults (the median age at diagnosis is 70 years). The slow progression
from asymptomatic stages and the late-onset of MM suggest fundamental differences
compared to many other hematopoietic system-related malignancies. The concept discussed
in this review is that age-related changes at the level of terminally differentiated
plasma cells act as the main risk factors for the development of MM. Epigenetic and
genetic changes that characterize both MM development and normal aging are highlighted.
The relationships between cellular aging processes, genetic mosaicism in plasma cells,
and risk for MM and the stochastic processes contributing to clonal selection and
expansion of mutated plasma cells are investigated. In line with the DNA damage accumulation
theory of aging, in this review, the evolution of monoclonal gammopathy to symptomatic
MM is considered. Therapeutic consequences of age-dependent comorbidities that lead
to frailty and have fundamental influence on treatment outcome are described. The
importance of considering geriatric states when planning the life-long treatment course
of an elderly MM patient in order to achieve maximal therapeutic benefit is emphasized.